Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson’s Disease

There are currently no treatments that stop or slow the progression of Parkinson's disease (PD). Case–control genome‐wide association studies have identified variants associated with disease risk, but not progression. The objective of the current study was to identify genetic variants associated with PD progression.

[1]  H. Berendse,et al.  A Large‐Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands , 2020, Movement disorders : official journal of the Movement Disorder Society.

[2]  Y. Asmann,et al.  APOE4 exacerbates α-synuclein pathology and related toxicity independent of amyloid , 2020, Science Translational Medicine.

[3]  Sonja W. Scholz,et al.  Common variation at the LRRK2 locus is associated with survival in the primary tauopathy progressive supranuclear palsy , 2020, bioRxiv.

[4]  Sonja W. Scholz,et al.  Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies , 2019, The Lancet Neurology.

[5]  D. Hernandez,et al.  Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts , 2019, Movement disorders : official journal of the Movement Disorder Society.

[6]  Y. Ben-Shlomo,et al.  Blood biomarkers with Parkinson's disease clusters and prognosis: The oxford discovery cohort , 2019, Movement disorders : official journal of the Movement Disorder Society.

[7]  B. Cullen,et al.  Neuropathology of dementia in patients with Parkinson’s disease: a systematic review of autopsy studies , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[8]  Bastiaan R Bloem,et al.  Measuring Parkinson's disease over time: The real‐world within‐subject reliability of the MDS‐UPDRS , 2019, Movement disorders : official journal of the Movement Disorder Society.

[9]  D. Hernandez,et al.  Genetic risk of Parkinson disease and progression: , 2019, Neurology. Genetics.

[10]  Sonja W. Scholz,et al.  Parkinson's disease age at onset genome‐wide association study: Defining heritability, genetic loci, and α‐synuclein mechanisms , 2019, Movement disorders : official journal of the Movement Disorder Society.

[11]  A. Lang,et al.  Randomized Delayed‐Start Trial of Levodopa in Parkinson's Disease , 2019, The New England journal of medicine.

[12]  R. Barker,et al.  Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[13]  G. Schellenberg,et al.  Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci , 2018, Molecular Neurodegeneration.

[14]  A. Nobre,et al.  APOE genotype and cognition in healthy individuals at risk of Alzheimer's disease: A review , 2018, Cortex.

[15]  Z. Gan-Or,et al.  GBA-Associated Parkinson’s Disease and Other Synucleinopathies , 2018, Current Neurology and Neuroscience Reports.

[16]  A. Bithell,et al.  2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling , 2018, Molecular Neurodegeneration.

[17]  Alzheimer’s Disease Neuroimaging Initiative,et al.  Genome-wide significant risk factors on chromosome 19 and the APOE locus , 2018, Oncotarget.

[18]  O. Tysnes,et al.  Alzheimer disease associated variants in SORL1 accelerate dementia development in Parkinson disease , 2018, Neuroscience Letters.

[19]  R. Barker,et al.  Features of GBA-associated Parkinson’s disease at presentation in the UK Tracking Parkinson’s study , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[20]  N. Weston,et al.  The Potential of Stem Cells in Treatment of Traumatic Brain Injury , 2018, Current Neurology and Neuroscience Reports.

[21]  Erdogan Taskesen,et al.  Functional mapping and annotation of genetic associations with FUMA , 2017, Nature Communications.

[22]  B. Hayete,et al.  Large-scale identification of clinical and genetic predictors of Parkinson’s disease motor progression in newly-diagnosed patients: a longitudinal cohort study and validation , 2017, The Lancet Neurology.

[23]  Enrico Amico,et al.  Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. , 2017, The Lancet. Neurology.

[24]  L. Pihlstrøm,et al.  Genetic risk factors for cognitive decline in Parkinson's disease: a review of the literature , 2017, European journal of neurology.

[25]  J. Schott,et al.  Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study , 2017, The Lancet Neurology.

[26]  M. Albert,et al.  Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. , 2016, JAMA neurology.

[27]  R. Barker,et al.  Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[28]  C. Mariani,et al.  Survival and dementia in GBA‐associated Parkinson's disease: The mutation matters , 2016, Annals of neurology.

[29]  R. Barker,et al.  Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's , 2016, Annals of neurology.

[30]  P. Deyn,et al.  Mutations in glucocerebrosidase are a major genetic risk factor for Parkinson’s disease and increase susceptibility to dementia in a Flanders-Belgian cohort , 2016, Neuroscience Letters.

[31]  V. Fung,et al.  Variants in the SNCA gene associate with motor progression while variants in the MAPT gene associate with the severity of Parkinson's disease. , 2016, Parkinsonism & related disorders.

[32]  Xiaowei Zhan,et al.  RVTESTS: an efficient and comprehensive tool for rare variant association analysis using sequence data , 2016, Bioinform..

[33]  R. Barker,et al.  Tracking Parkinson’s: Study Design and Baseline Patient Data , 2015, Journal of Parkinson's disease.

[34]  Margaret Sutherland,et al.  Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study , 2015, The Lancet Neurology.

[35]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[36]  M. Daly,et al.  An Atlas of Genetic Correlations across Human Diseases and Traits , 2015, Nature Genetics.

[37]  Joris M. Mooij,et al.  MAGMA: Generalized Gene-Set Analysis of GWAS Data , 2015, PLoS Comput. Biol..

[38]  D. Berg,et al.  GBA‐associated Parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study , 2015, Movement disorders : official journal of the Movement Disorder Society.

[39]  M. Daly,et al.  LD Score regression distinguishes confounding from polygenicity in genome-wide association studies , 2014, Nature Genetics.

[40]  Joris M. Mooij,et al.  MAGMA: Generalized Gene-Set Analysis of GWAS Data , 2015, PLoS Comput. Biol..

[41]  T. Montine,et al.  APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. , 2014, JAMA neurology.

[42]  David J. Brooks,et al.  Genetic impact on cognition and brain function in newly diagnosed Parkinson’s disease: ICICLE-PD study , 2014, Brain : a journal of neurology.

[43]  H. Shill,et al.  Low clinical diagnostic accuracy of early vs advanced Parkinson disease , 2014, Neurology.

[44]  Sebastian M. Armasu,et al.  Does α-synuclein have a dual and opposing effect in preclinical vs. clinical Parkinson's disease? , 2014, Parkinsonism & related disorders.

[45]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[46]  Y. Ben-Shlomo,et al.  The influence of age and gender on motor and non-motor features of early Parkinson's disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. , 2014, Parkinsonism & Related Disorders.

[47]  T. Robbins,et al.  The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[48]  M. Ban,et al.  Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. , 2013, Brain : a journal of neurology.

[49]  Daniel Weintraub,et al.  APOE ε4 increases risk for dementia in pure synucleinopathies. , 2013, JAMA neurology.

[50]  David N. Rider,et al.  Genomic determinants of motor and cognitive outcomes in Parkinson's disease. , 2012, Parkinsonism & related disorders.

[51]  R. Hauser,et al.  [123I]FP‐CIT (DaTscan) SPECT Brain Imaging in Patients with Suspected Parkinsonian Syndromes , 2012, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[52]  Beate Ritz,et al.  α-Synuclein Genetic Variants Predict Faster Motor Symptom Progression in Idiopathic Parkinson Disease , 2012, PloS one.

[53]  K. Marder,et al.  Cognitive performance of GBA mutation carriers with early-onset PD , 2012, Neurology.

[54]  M. Blurton-Jones,et al.  Examining the mechanisms that link β-amyloid and α-synuclein pathologies , 2012, Alzheimer's Research & Therapy.

[55]  A. Siderowf,et al.  Genetic influences on cognitive decline in Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[56]  P. Visscher,et al.  Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits , 2012, Nature Genetics.

[57]  Wendy J Mack,et al.  Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review , 2011, Alzheimer's Research & Therapy.

[58]  A. Singleton,et al.  The Parkinson Progression Marker Initiative (PPMI) , 2011, Progress in Neurobiology.

[59]  Thomas Foltynie,et al.  The natural history of treated Parkinson's disease in an incident, community based cohort , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[60]  P. Visscher,et al.  GCTA: a tool for genome-wide complex trait analysis. , 2011, American journal of human genetics.

[61]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[62]  G. Halliday,et al.  Interaction between α-synuclein and tau genotypes and the progression of Parkinson's disease. , 2011, Journal of Parkinson's disease.

[63]  M H Cole,et al.  Predictors of future falls in Parkinson disease , 2010, Neurology.

[64]  Eden R Martin,et al.  Genome‐Wide Association Study Confirms SNPs in SNCA and the MAPT Region as Common Risk Factors for Parkinson Disease , 2010, Annals of human genetics.

[65]  D. Berg,et al.  Progression of Parkinson's disease in the clinical phase: potential markers , 2009, The Lancet Neurology.

[66]  Thomas Foltynie,et al.  The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. , 2009, Brain : a journal of neurology.

[67]  A. Spottke,et al.  Comparative responsiveness of Parkinson's disease scales to change over time , 2009, Movement disorders : official journal of the Movement Disorder Society.

[68]  A. Goris,et al.  Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s Disease , 2009, Journal of Neurology.

[69]  M. Ban,et al.  Tau and α‐synuclein in susceptibility to, and dementia in, Parkinson's disease , 2007 .

[70]  Nuala A Sheehan,et al.  Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressure , 2005, Statistics in medicine.

[71]  C. Paulusma,et al.  The type 4 subfamily of P-type ATPases, putative aminophospholipid translocases with a role in human disease. , 2005, Biochimica et biophysica acta.

[72]  W. Poewe,et al.  Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[73]  Makoto Hashimoto,et al.  β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[74]  C. Marsden,et al.  A new society, a new journal, and a new medium , 1986 .